Key result
Hepatic fibrosis severity in MASLD is linked to higher CAC burden.
Why the study?
Cardiovascular disease is the leading cause of mortality in MASLD, reflecting shared pathophysiologic mechanisms with atherosclerotic cardiovascular disease, which has implications for risk stratification and multidisciplinary care.
Recognition of MASLD as a systemic cardiometabolic disorder highlights the need for integrated cardiovascular risk stratification and multidisciplinary care.
Supports integrated CV risk stratification and multidisciplinary care in MASLD; reinforces its systemic cardiometabolic nature.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is increasingly recognized as an important cardiovascular risk modifier. Cardiovascular disease is the leading cause of mortality among individuals with MASLD, reflecting shared pathophysiologic mechanisms with atherosclerotic cardiovascular disease. These include insulin resistance, lipotoxicity, oxidative stress, chronic inflammation, endothelial dysfunction, and progressive fibrogenesis, which contribute to both hepatic disease progression and atherosclerotic plaque development. Noninvasive biomarkers and imaging modalities provide complementary tools for integrated risk assessment. Serum measures of insulin resistance, atherogenic dyslipidemia, inflammation, and composite fibrosis scores are associated with both liver disease severity and cardiovascular risk. Vibration-controlled transient elastography enables noninvasive assessment of hepatic fibrosis and steatosis, while coronary artery calcium scoring is a robust predictor of subclinical atherosclerosis and cardiovascular events. Increasing evidence demonstrates a positive association between hepatic fibrosis severity and coronary artery calcium burden, supporting combined hepatic and cardiovascular evaluation in patients with MASLD. Therapeutic strategies targeting shared cardiometabolic pathways offer a potential dual benefit. Lifestyle modification remains foundational for improving hepatic disease activity and reducing cardiovascular risk. Statins are safe in MASLD and provide established cardiovascular protection. Glucagon-like peptide-1 receptor agonists and other emerging metabolic therapies demonstrate promise in improving liver disease activity while favorably modifying cardiometabolic risk factors. Recognition of MASLD as a systemic cardiometabolic disorder has important implications for cardiovascular risk stratification and multidisciplinary care.
No takes yet. Share an insight, caveat, or question.
Drogy et al. (2026) studied this question. Hepatic fibrosis severity in metabolic dysfunction-associated steatotic liver disease is positively associated with coronary artery calcium burden.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: